Phase III study of 2-weekly versus 3-weekly docetaxel for castration-resistant advanced prostate cancer

Source: Lancet Oncology Area: News According to the results of a Phase III study published early online in The Lancet Oncology, a 2-weekly docetaxel regimen was well tolerated and improved time to treatment failure compared with the standard 3-weekly regimen in men with hormone-refractory prostate cancer.   The authors note that androgen deprivation is a standard treatment for advanced prostate cancer; it is not however curative and most patients develop castration-resistant disease within a median of 2 years. Several treatment options are available for patients with hormone-refractory prostate cancer, including docetaxel (IV every three weeks) plus prednisone. They hypothesised that 2-weekly administration of docetaxel would be better tolerated than 3-weekly docetaxel in this patient group, and could thus lead to longer times on treatment and better outcomes, and this was the basis of the current study.   This prospective, multicentre, open-label study included men with advanced prostate cancer ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news